SAN DIEGO – QuidelOrtho Corporation (NASDAQ:QDEL), a global provider of diagnostic solutions, today announced preliminary unaudited revenues for the fourth quarter of 2024 that align with the company’s previous financial projections. The firm anticipates reporting revenues ranging from $702 million to $707 million for the quarter ended December 29, 2024. According to InvestingPro data, the company’s stock has shown strong momentum with a 41% gain over the past six months, despite trading below its 52-week high of $74.04.
The expected revenues consist of approximately $561 million to $563 million from non-respiratory products and about $141 million to $143 million from respiratory products. These figures suggest the company’s performance is consistent with its financial guidance for the year. InvestingPro analysis indicates the company maintains a healthy gross profit margin of 47.6%, though it currently operates with a significant…
